Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
Trastuzumab deruxtecan plus pertuzumab led to a significantly lower risk of progression or death than THP when used as first-line treatment for HER2-positive advanced or metastatic breast cancer, with no new safety signals. (Funded by AstraZeneca and Daiichi Sankyo; DESTINY-Breast09 ClinicalTrials.gov number, NCT04784715.).
Authors
- Winnie Yeo (ORCID: https://orcid.org/0000-0002-0863-8469)
- Toshinari Yamashita (ORCID: https://orcid.org/0000-0002-6479-1660)
- Pia Herbolsheimer
- Mehmet Alı Nahıt Şendur (ORCID: https://orcid.org/0000-0001-7021-6139)
- Jagdish Shetty (ORCID: https://orcid.org/0000-0003-4001-4987)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Romualdo Barroso‐Sousa (ORCID: https://orcid.org/0000-0002-1825-9876)
- Mothaffar F. Rimawi (ORCID: https://orcid.org/0000-0002-4284-5656)
- Yasemi̇n Kemal (ORCID: https://orcid.org/0000-0002-1175-9085)
- Zefei Jiang (ORCID: https://orcid.org/0000-0002-4295-0173)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Sibylle Loibl (ORCID: https://orcid.org/0000-0001-6488-4958)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- M.L. Casalnuovo
- Masakazu Toi (ORCID: https://orcid.org/0000-0003-1488-9958)
- Jie Liu (ORCID: https://orcid.org/0000-0001-8883-5712)
- Qingyuan Zhang (ORCID: https://orcid.org/0000-0001-7618-4393)
- Yee Soo Chae
- Michael Danso
- Mukesh Chaudhari
Institutions
- Goethe University Frankfurt (DE)
- Hebron University (PS)
- Harvard University (US)
- Ankara University (TR)
- Harbin Medical University (CN)
- German Cancer Research Center (DE)
- Baylor College of Medicine (US)
- Heidelberg University (DE)
- Kyungpook National University Hospital (KR)
- University Hospital Heidelberg (DE)
- Samsung Medical Center (KR)
- Kanagawa Prefectural Hospital Organization (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Virginia Oncology Associates (US)
- 307th Hospital of Chinese People’s Liberation Army (CN)
- Memorial Ankara Hospital (TR)
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (AR)
- Sarah Cannon (US)
- Third Affiliated Hospital of Harbin Medical University (CN)
- National Center for Tumor Diseases (DE)
- AstraZeneca (Netherlands) (NL)
- Dana-Farber Cancer Institute (US)
- German Breast group (DE)
- HCG Cancer Centre (IN)
- AstraZeneca (Poland) (PL)
- Hospital Universitário de Brasília (BR)
- AstraZeneca (Spain) (ES)
- Kanagawa Cancer Center
- Istanbul University (TR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1056/nejmoa2508668
- Citations
- 18
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 18.82